Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1991 Oct;54(10):898–904. doi: 10.1136/jnnp.54.10.898

Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.

M Otsuka 1, Y Ichiya 1, S Hosokawa 1, Y Kuwabara 1, T Tahara 1, T Fukumura 1, M Kato 1, K Masuda 1, I Goto 1
PMCID: PMC1014575  PMID: 1744644

Abstract

Striatal blood flow, glucose metabolism and 18F-Dopa uptake were studied with positron emission tomography (PET) in eight non-demented patients with idiopathic Parkinson's disease and eight with atypical Parkinsonism. Patients with atypical Parkinsonism had no specific cause for the Parkinsonian symptoms and were clinically different from Parkinson's disease with lack of resting tremor and a poor response to dopaminergic drugs. Decreased 18F-Dopa uptake in the putamen was observed in patients with Parkinson's disease and atypical Parkinsonism compared with normal controls. 18F-Dopa uptake in the head of the caudate was also significantly reduced in both conditions but relatively less in Parkinson's disease. Decreased blood flow and glucose metabolism in the striatum associated with a global cerebral decrease were also observed in patients with atypical Parkinsonism compared with controls, while they were preserved in patients with Parkinson's disease, indicating affected neurons not only in the striatum but also in the cerebrum in patients with atypical Parkinsonism compared with patients with Parkinson's disease. The differences in the caudate 18F-Dopa uptake, and blood flow and glucose metabolism in the cerebrum including the striatum between Parkinson's disease and atypical Parkinsonism assessed by PET may be due to the differences in the pathophysiological mechanism between Parkinson's disease and atypical Parkinsonism.

Full text

PDF
898

Images in this article

900Image
on p.900
903Image
on p.903

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415–455. doi: 10.1016/0022-510x(73)90175-5. [DOI] [PubMed] [Google Scholar]
  2. Brooks D. J., Ibanez V., Sawle G. V., Quinn N., Lees A. J., Mathias C. J., Bannister R., Marsden C. D., Frackowiak R. S. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990 Oct;28(4):547–555. doi: 10.1002/ana.410280412. [DOI] [PubMed] [Google Scholar]
  3. Brooks R. A. Alternative formula for glucose utilization using labeled deoxyglucose. J Nucl Med. 1982 Jun;23(6):538–539. [PubMed] [Google Scholar]
  4. De Volder A. G., Francart J., Laterre C., Dooms G., Bol A., Michel C., Goffinet A. M. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol. 1989 Aug;26(2):239–247. doi: 10.1002/ana.410260210. [DOI] [PubMed] [Google Scholar]
  5. Frackowiak R. S., Lenzi G. L., Jones T., Heather J. D. Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. J Comput Assist Tomogr. 1980 Dec;4(6):727–736. doi: 10.1097/00004728-198012000-00001. [DOI] [PubMed] [Google Scholar]
  6. Garnett E. S., Lang A. E., Chirakal R., Firnau G., Nahmias C. A rostrocaudal gradient for aromatic acid decarboxylase in the human striatum. Can J Neurol Sci. 1987 Aug;14(3 Suppl):444–447. doi: 10.1017/s0317167100037884. [DOI] [PubMed] [Google Scholar]
  7. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  8. Hägglund J., Aquilonius S. M., Eckernäs S. A., Hartvig P., Lundquist H., Gullberg P., Långström B. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone. Acta Neurol Scand. 1987 Feb;75(2):87–94. doi: 10.1111/j.1600-0404.1987.tb07900.x. [DOI] [PubMed] [Google Scholar]
  9. Hökfelt T., Ungerstedt U. Electron and fluorescence microscopical studies on the nucleus caudatus putamen of the rat after unilateral lesions of ascending nigro-neostriatal dopamine neurons. Acta Physiol Scand. 1969 Aug;76(4):415–426. doi: 10.1111/j.1748-1716.1969.tb04489.x. [DOI] [PubMed] [Google Scholar]
  10. Kanno I., Miura S., Yamamoto S., Iida H., Murakami M., Takahashi K., Uemura K. Design and evaluation of a positron emission tomograph: HEADTOME III. J Comput Assist Tomogr. 1985 Sep-Oct;9(5):931–939. doi: 10.1097/00004728-198509000-00017. [DOI] [PubMed] [Google Scholar]
  11. Leenders K. L., Frackowiak R. S., Lees A. J. Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain. 1988 Jun;111(Pt 3):615–630. doi: 10.1093/brain/111.3.615. [DOI] [PubMed] [Google Scholar]
  12. Leenders K. L., Palmer A. J., Quinn N., Clark J. C., Firnau G., Garnett E. S., Nahmias C., Jones T., Marsden C. D. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986 Aug;49(8):853–860. doi: 10.1136/jnnp.49.8.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Martin W. R., Stoessl A. J., Adam M. J., Ammann W., Bergstrom M., Harrop R., Laihinen A., Rogers J. G., Ruth T. J., Sayre C. I. Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism. Adv Neurol. 1987;45:95–98. [PubMed] [Google Scholar]
  14. Nahmias C., Garnett E. S., Firnau G., Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci. 1985 Jul;69(3):223–230. doi: 10.1016/0022-510x(85)90135-2. [DOI] [PubMed] [Google Scholar]
  15. Otsuka M., Ichiya Y., Kuwabara Y., Miyake Y., Tahara T., Masuda K., Hosokawa S., Goto I., Kato M., Ichimiya A. Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy. Ann Nucl Med. 1989 Nov;3(3):111–118. doi: 10.1007/BF03178296. [DOI] [PubMed] [Google Scholar]
  16. Phelps M. E., Huang S. C., Hoffman E. J., Selin C., Sokoloff L., Kuhl D. E. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979 Nov;6(5):371–388. doi: 10.1002/ana.410060502. [DOI] [PubMed] [Google Scholar]
  17. Rougemont D., Baron J. C., Collard P., Bustany P., Comar D., Agid Y. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1984 Aug;47(8):824–830. doi: 10.1136/jnnp.47.8.824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sokoloff L., Reivich M., Kennedy C., Des Rosiers M. H., Patlak C. S., Pettigrew K. D., Sakurada O., Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977 May;28(5):897–916. doi: 10.1111/j.1471-4159.1977.tb10649.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES